Boehringer Ingelheim (Germany) has signed a research collaboration and license agreement with Domain Therapeutics (France) on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area.
The collaboration combines the expertise of Domain Therapeutics in the discovery of GPCR targeting drugs in CNS, oncology and immuno-oncology, with Boehringer Ingelheim’s expertise in the discovery and clinical development of therapeutics on multiple indications.
Domain Therapeutics will use its proprietary platforms, DTect-All and bioSens-All, which enable a comprehensive characterization of small molecule GPCR binders for the screening and characterization of potential lead compounds. The company will be eligible for an upfront payment, discovery, development and commercial milestone payments as well as royalties on sales.
Domain Therapeutics engages in the discovery and development of small molecules targeting G protein-coupled receptors (GPCRs). The company offers therapeutics for the treatment of central nervous system (CNS) diseases and cancer; and develops new drug candidates, allosteric modulators, and biased ligands. Domain Therapeutics was founded in 2001 and is based in Illkirch-Graffenstaden (France).